Menu
Menu
Company Contact: Daniel Burnett
Legal Entity Type: C-Corp
Company Type: Medical Device
Company Stage: FDA Approved / Early Launch
No. of Employees: 4
Desired Financial Amount: $2M
Background
Company Background
Based on technology our of the Theranova incubator in San Francisco, JustAir was formed in San Antonio to take advantage of R&D and manufacturing expertise in San Antonio. The JustAir Pro device is the ONLY mask that is capable of preventing carbon dioxide toxicity while also preventing spread of viral particles to those around the potentially asymptomatic (or presymptomatic) user.
Management
Daniel Burnett, MD, MBA- CEO
Eduardo Quintinilla- Plant Manager
Board of directors
Daniel Burnett, MD, MBA- CEO
Alan Chesler- Ehrenberg Chesler Capital Partners
Product / Service
disease area / application
Personal Protective Equipment
product / Service
When properly fit Elastomeric Half-mask Respirators (EHMRs) do a good job of filtering inhaled air and exhaled air but, even if professionally fit with the initial wear, the EHMR can lose its fit throughout the day. Also, the EHMR causes carbon dioxide retention in inhaled air (Rhee 2020), increase in facial temperatures and general discomfort. The JustAir EHMR with breath assist and continuous Fit Check Algorithm solves all of these problems by:
1) Providing N100 filtered air at a flow rate of ~100L/min to keep up with the users breathing even during exertion
2) Filtering exhaled air to N99 standards as verified by an outside lab (ICS, OH)
3) Continuously monitoring intramask pressure to immediately detect fit failure
This combination makes the JustAir Pro the only solution to truly and comfortably protect the users and those around them…and at half the cost of most Powered air Purifying Respirators (PAPR).
technology / ip
Patented and patent pending on filtration of air blowing OUT of the EHMR and continuous fit check.
distribution channels
Seeking channels
market size
16M healthcare practitioners that wear PPE for more than 3 hours per day.
competition
3M and other mask makers. No other mask provides N100 filtration of inhaled air and N99 filtration of exhaled air.
Financials
Desired financial amount
$2M
previous funding
$2.6M from investors, mostly in San Antonio. Submitted NIH grant for $1.7M
current financials
$15K per month burn awaiting NIOSH approval.
financial use
Build inventory and fill institutional sale following NIOSH approval.
revenue
Direct pay from hospitals and healthcare practitioners.
exit strategy
Sale to 3M or other mask company. NIOSH approval is expected to advance discussions and expedite a potential exit.